Compare Heron Therapeutics Inc (HRTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Yum China Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Yum China Holdings Inc trades at $42.88 (market cap $14.11B). The key difference: Yum China Holdings Inc is far larger — about 207.5× Heron Therapeutics Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Yum China Holdings Inc for 77 Days on average.
| HRTX | YUMC | |
|---|---|---|
Market Cap | $68.01M | $14.11B |
Volume | 1,891,941 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $57.95 |
52-Week Low | $0.27 | $39.98 |
Typical Hold Time | 35 Days | 77 Days |
Enterprise Value | $174.75M | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
YUMC trades at $42.92, up 5.58% today, with strong analyst support (73.68% buy ratings) but technical indicators show bearish momentum. The company demonstrates solid fundamentals with consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, and net income improving to $929M. Recent strategic moves include the $1.2B acquisition of Pizza Hut China brand ownership and expansion of Pizza Hut Burger Bars to 300 locations.
YUMC presents a value opportunity with reasonable valuation (P/E 15.3, P/S 1.2) and strong profitability (ROE 17.5%), though technical weakness and China economic exposure pose near-term risks. The stock's 25.6% analyst upside potential and consistent earnings beats support long-term growth prospects despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
